Related Experiment Video

Updated: Oct 5, 2025

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
10:24

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

12.5K

High-Dose Convalescent Plasma for Treatment of Severe COVID-19

Gil C De Santis, Luciana Correa Oliveira, Pedro M M Garibaldi

    Emerging Infectious Diseases
    |January 26, 2022
    PubMed

    Insights

    High-dose COVID-19 convalescent plasma (CCP) transfusions did not improve survival rates for severe COVID-19 patients. This randomized trial found no significant benefit in mortality or hospital stay duration for CCP recipients.

    Area of Science:

    • Infectious Diseases
    • Hematology
    • Critical Care Medicine

    Background:

    • Severe COVID-19 presents a significant global health challenge.
    • Convalescent plasma (CCP) has been explored as a potential therapeutic option.
    • The efficacy of high-dose CCP in early-stage severe COVID-19 remains under investigation.

    Purpose of the Study:

    • To evaluate the effectiveness of high-dose COVID-19 convalescent plasma (CCP) transfusion.
    • To determine if CCP benefits patients with severe COVID-19 within 10 days of symptom onset.
    • To compare mortality rates and clinical outcomes between CCP and standard treatment groups.

    Main Methods:

    • A multicenter randomized trial was conducted in Brazil.
    • 107 patients with severe COVID-19 within 10 days of symptom onset were enrolled.
    • Patients received either high-dose CCP (600 mL/d for 3 days) plus standard care or standard care alone.

    Main Results:

    • At 30 days, mortality was 22% in the CCP group versus 25% in the control group.
    • At 60 days, mortality was 31% in the CCP group versus 35% in the control group.
    • No significant differences were observed in ventilator-free days or hospital-free days between groups.

    Conclusions:

    • High-dose CCP transfusions administered within 10 days of symptom onset did not demonstrate a benefit for severe COVID-19 patients.
    • The study suggests that this specific high-dose CCP regimen is not effective in improving outcomes for this patient population.
    • Further research may be needed to explore alternative dosing strategies or patient selection criteria for CCP therapy.

    Keywords:
    2019 novel coronavirus diseaseBrazilCOVID-19SARS-CoV-2convalescent plasmacoronavirus diseaseneutralizing antibodypassive immunizationrespiratory infectionssevere acute respiratory syndrome coronavirus 2viruseszoonoses

    More Related Videos

    Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant08:52

    Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

    Published on: May 27, 2011

    17.4K
    Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-1908:48

    Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

    Published on: February 16, 2022

    3.0K

    Related Concept Videos

    Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

    Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

    Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
    Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
    339
    Pneumonia IV: Management01:28

    Pneumonia IV: Management

    The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
    Bacterial Pneumonia Treatment
    For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
    487
    Heart Failure VI: Adjunct Therapies01:22

    Heart Failure VI: Adjunct Therapies

    Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
    48
    Acute Respiratory Failure-IV01:23

    Acute Respiratory Failure-IV

    Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
    261
    Acute Respiratory Failure-II01:21

    Acute Respiratory Failure-II

    Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
    The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
    417